Abstract

The Cancer Center Support (CORE) Grant supports the peer-funded research activities of The University of Texas M.D. Anderson Cancer Center in six broad programmatic areas: Biomathematics, Cell and Tumor Cell Biology, Genetics, Immunology, Experimental Therapeutic and Cancer Prevention and Control. It does so by providing support for the resources required for the continuation and the expansion of our diverse clinical and basic science research activities. The shared resources supported by the Core Grant include: Automated Cytometry and Cell Sorter Laboratory, Scanning Electron Microscopy Facility, Tissue Procurement and Banking Facility, Centralized Histopathology Laboratory, Research Animal Support Facility, Veterinary Resources Support Facility, Cancer Information Systems Resource, Biostatistical Resource Group, Clinical Trials Support, Synthetic Antigen Laboratory, and Macromolecular Synthesis and Analysis Facility. The Cancer Center Support (CORE) Grant also provides Developmental Funds to support new investigators with start-up funds or to initiate new shared facilities, and support for an external advisory committee for Planning and Evaluation.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-19
Application #
3101604
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1978-07-01
Project End
1997-06-30
Budget Start
1993-08-01
Budget End
1994-06-30
Support Year
19
Fiscal Year
1993
Total Cost
Indirect Cost

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360
Ellrott, Kyle; Bailey, Matthew H; Saksena, Gordon et al. (2018) Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6:271-281.e7
White, Matthew C; Schroeder, Rebecca D; Zhu, Keyi et al. (2018) HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells. Oncogene 37:4413-4427
Abaza, Yasmin; Hidalgo-Lopez, Juliana E; Verstovsek, Srdan et al. (2018) Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85
McGrail, Daniel J; Federico, Lorenzo; Li, Yongsheng et al. (2018) Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9:1317
Li, Carrie J; Jiang, Changying; Liu, Yang et al. (2018) Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther :
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Raber, Benjamin; Bea, Vivian J; Bedrosian, Isabelle (2018) How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. Magn Reson Imaging Clin N Am 26:281-288
Li, Roger; Metcalfe, Michael J; Ferguson 3rd, James E et al. (2018) Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121:244-251

Showing the most recent 10 out of 12418 publications